3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
2
Glioma
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Glioblastoma
1
Endometrial Neoplasms
1
Endometrial Cancer Recurrent
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
pembrolizumab
29
Capecitabine
24
Bevacizumab
23
Cyclophosphamide
22
Gemcitabine
21
Paclitaxel
20
Nivolumab
19
Fluorouracil
19
Docetaxel
18
aldesleukin
17
Leucovorin
17
Irinotecan
17
Oxaliplatin
15
Interleukin-2
14
Radiosurgery
13
Cisplatin
13
Cetuximab
13
fludarabine
12
Carboplatin
12
Albumin-Bound Paclitaxel
11
fludarabine phosphate
10
Ipilimumab
10
Drug Therapy
10
Doxorubicin
10
Sunitinib
9
Radiotherapy
9
Everolimus
9
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
Temozolomide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm Metastasis
×
TIC10 compound
×
Clear all
NCT03791398
2023-02-17
379
Brown University
Phase 1/2
Terminated
13 enrolled
11 charts